Session Description:

This symposium is organized by PVI, PeerView Institute for Medical Education and is supported by an educational grant from Industry.Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this live in-person and virtual CME/EACCME-certified educational symposium, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emerging biomarkers that can aid in the early diagnosis of AD. They will also explore the mechanisms of action, efficacy, and safety data for promising disease-modifying therapies in development for the treatment of AD. Using patient case examples to frame the discussion, the expert faculty panel will also provide practical guidance on how neurologists can effectively and safely integrate new diagnostic tools and disease-modifying therapies into clinical practice.

Session Description:

Alzheimer’s Disease is a multifactorial disorder, yet therapeutic focus is often limited to specific pathways. This session will expand thinking to how multiple mechanisms acting in parallel can be understood, approached and targeted to deliver accurate diagnosis tools and impactful therapies. Through basic science to uncover systemic influences on the brain, cutting edge biomarkers to assess a plethora of mechanisms and innovative approaches now being used in the clinic, we are reaching reality in harnessing this multimodality. This fresh perspective in approaches to AD diagnosis and therapeutic development builds on decades of research in the field, giving birth to accurate biomarkers and eventually to new generation therapies.

Session Description:

Come and listen to the diagnostic algorithm developed by Gael Chetelat and her European and US based colleagues at the first EANM focus group. The meeting will cover the three pathways described in their recent 2020 Lancet Neurology paper as well as exploring new dimensions for biomarker utility particularly as novel therapies for both AD and PD emerge.